starpharma

Dr. Jackie Fairley CEO

STARPHARMA HOLDINGS LIMITED ASX:SPL; OTCQX:SPHRY

17 May 2016



This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Summary



> ASX300 company (ASX:SPL) and (OTCQX:SPHRY); Market Cap ~A\$250M

Three business areas: DEP[™] drug delivery platform, VivaGel[®] and Agrochemicals supporting a deep portfolio of products under development or on market

- DEP™ drug delivery platform has the potential to produce a portfolio of new DEP™ products with multiple revenue streams
 - Multi product DEP[™] license with AstraZeneca valued up to US\$126M in milestones plus royalties (first product) and up to US\$93M plus royalties for subsequent products
 - DEP[™] docetaxel and internal DEP[™] pipeline has potential to deliver multiple and high value additional deals
 - DEP[™] based partnered programs in place and under discussion with multiple leading pharmaceutical companies
- > VivaGel[®] portfolio focused on women's and sexual health
 - VivaGel[®] condom launched in Australia with further approvals and launches to follow
 - VivaGel[®] BV Two products for Bacterial Vaginosis first approved in Europe, second in phase 3 clinical trial
- Agrochemical program based on SPL's novel dendrimer technology with extensive commercial partnerships plus internal programs
- Strong cash position: Cash balance of A\$51.1M (31/3/16)




Starpharma's headquarters and laboratories Melbourne, Australia



Starpharma is a global leader in dendrimer nanoparticles

Starpharma's portfolio - internal programs and commercial partnerships with leading companies




starpharma

DEP™ Drug Delivery

DEP™ Drug Delivery

Dual Strategy

Provides technical, IP and financial leverage Increases commercial opportunities Reduces invested capital De-risks



Extensive partner engagement to maximise commercial outcomes



Starpharma's DEP[™] Delivery License with AstraZeneca (LON:AZN)




"SPL estimates that each product successfully commercialised under this agreement could be worth around US\$450m to Starpharma and, depending on the range of indications and degree of commercial success in the market, potentially significantly more"

- AZ multi-product license for use of DEP[™] delivery platform for the development and commercialisation of proprietary AZ compounds directed at a defined family of targets
- SPL eligible to receive development, launch and sales milestones for the first AZ DEP[™] product of up to USD\$126m plus royalties & up to USD\$93m in milestones for each subsequent qualifying AZ DEP[™] products
- Tiered royalties on net sales
- AZ funds all development and commercialisation costs
- DEP[™] docetaxel not impacted and agreement field allows for multiple other DEP[™] licences
- Received US\$2M in H1 FY2016

"We already have a long-standing and successful working relationship with Starpharma. This license agreement will enable us to further harness the DEP™ technology and evaluate its potential across novel molecules within our oncology portfolio." Dr Susan Galbraith, Head of the Oncology Innovative Medicines Unit at AstraZeneca








Starpharma's DEP™ Docetaxel: Multiple Benefits

- Docetaxel (Taxotere®) is a blockbuster chemotherapeutic
- Docetaxel sales: US\$3.1B (2012)
- Docetaxel is used in major cancer types including breast, prostate, lung and ovarian cancer
- Starpharma's patented DEP[™] docetaxel is a nanoparticle formulation with multiple advantages compared to Taxotere[®]
- DEP[™] patents filed will offer coverage to 2032 (potential for further filings)
- DEP[™] docetaxel Phase 1 trial in Australia promising preliminary findings with no neutropenia





1. Elimination of major dose-limiting side effect

(neutropenia)

- 2. Detergent-free formulation (less toxic)
- 3. Tumour-targeting (40-70x more)
- 4. Extended duration (half-life)
- 5. Improved efficacy (breast, ovarian, prostate)







Patents filed will offer coverage to 2032 (potential for further filings)



DEP™ Docetaxel Clinical Program

Phase 1 Clinical Trial: Encouraging anticancer activity and no neutropenia

- Open label study, ~25-30 cancer patients with advanced solid tumours
- DEP[™] docetaxel administered intravenously (unlike Taxotere[®] no steroid pre-treatment or anti-emetics required)

Current Status:

- Patients dosed with multiple cycles (up to 6 cycles); dosed up to & above commonly used Taxotere[®] dose of 75mg/m²
- Dose optimisation & expansion now underway to identify dose for Phase 2; more than 75% recruited

Interim Findings:

- No neutropenia (docetaxel DLT) or alopecia reported
 - Compared to Taxotere® where severe neutropenia is suffered by 75% of patients dosed 60mg/m²^
- A significant proportion of DEP[™] docetaxel patients have exhibited efficacy signals/anticancer activity including at low doses and in cancers not expected to be responsive to docetaxel:
 - Efficacy signals seen in pancreatic cancer (stable disease > 20 weeks), prostate, lung, H&N, gastro-oesophageal and glioblastoma (brain tumour)


Phase 2:

Planning now underway with CROs and key opinion leaders for Phase 2 trial including design and indications; clinical trial material manufacture underway


^ Taxotere PI



Targeted DEP[™] outperforms leading treatments in ovarian cancer model




Efficacy of HER2-targeted DEP™ Conjugate vs Kadcyla® and Herceptin® in an Ovarian* Cancer Model



*SKOV-3 Ovarian cancer xenograft in NOD-SCID mice (5-6/group) Saline, Kadcyla® (10mg/kg) and Targeted DEP[™] conjugate were dosed once/wk for 3 wks; Herceptin® (20mg/kg) dosed twice/wk for 3 wks.

Statistical analysis at day 40. Kadcyla® vs Targeted DEP™; P <0.0001. (ANOVA followed by Tukey's post hoc test).

- SPL's novel antibody-targeted DEP[™] conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model
- The antibody-targeted DEP[™] conjugate (using Herceptin as the targeting group) significantly outperformed both Roche's Kadcyla[®] (T-DM1) and the monoclonal antibody Herceptin[®] (Trastuzumab) alone
 - Targeted DEP™ of significant commercial interest in partnering; patent filings underway







VivaGel® Portfolio

- VivaGel[®] is a proprietary antimicrobial dendrimer active in HIV, HSV, HPV and bacterial vaginosis (BV)
- VivaGel[®] BV (bacterial vaginosis)



- Symptomatic Relief EU approved, ANZ licence signed with further commercial discussions underway; launch expected 2016
- Prevention of Recurrent BV Phase 3 clinical program underway in North America, Europe, and Asia (under SPA)
- VivaGel[®] (antiviral) condom rights licensed to Ansell and Okamoto; launched in Australia, regulatory processes underway for multiple other regions,
- MOU signed for supply of VivaGel[®] condom to Chinese Government Market

VivaGel Portfolio			Research	Pre- clinical	Phase I	Phase II	Phase III	Reg. approval	Market launch
Antimicrobial / Antiviral (SPL7013)	VivaGel [®] BV	BV Symptomatic Relief							
	VivaGel [®] BV	BV Prevention of Recurrence							
	VivaGel [®] Coated Condom	Ansell Common							
									ompleted Planned

VivaGel® Condom: A compelling, world-first product

- Based on innovative, Australian technology
- Typical condom use associated with an estimated:
 - 80% reduction in HIV infection, only a 30% lower risk of genital herpes (HSV-2) infection, and a
 70% reduced risk of a new HPV infection
- VivaGel[®] Condom: contains the potent antiviral VivaGel[®] shown in laboratory studies to inactivate up to 99.9% HIV, HPV & herpes - intended to help reduce risk of exposure to viruses via inactivation (as well as the STI barrier protection a condom provides)
- Licensed to global market leaders:
 - Ansell No. 2 globally based on sales; leading brand in regions including Australia
 - Okamoto No. 1 in Japan
 - Further commercial discussions underway including supply of VivaGel[®] condom to Chinese Government Market
- Currently selling in Australia in retail outlets and online under LifeStyles® Dual Protect™ brand
- Regulatory processes underway and significantly advanced in additional regions
- Branded global condom market: \$1.1B
- VivaGel[®] condom patents to 2027



DUAL PROTECT™

with VivaGel[®] : lubricated with

VivaGel[®] which has been shown

to inactivate up

to 99.9% HIV.

HPV and HSV

(Herpes) in

laboratory

studies



THE WORLD'S

FIRST ANTI-VIRAL

CONDOM

VivaGel[®] shows potent activity against Zika virus

Zika outbreak declared a 'global emergency' by WHO Australian Team taking Dual Protect™ VivaGel® Condoms to Rio

Aust Olympians get extra Zika protection

Published 18 Hay 2016 (AED/I)





Australia's Olympians will be provided with condoms treated with a gel that in lab studies has shown "near-complete" antiviral protection against Zika.

WORLD BRAZIL

WHO Says Pregnant Women Should Avoid Rio

Olympics Due to Zika



Brazil has more than 1 Million reported cases

ΓΙΜΕ



0

🛃 Follow

AUSTRALI

Scientists predict #Zika will become part of the new normal for Americans, requiring routine vaccinations.



Dual Protect™ the world's only antiviral condom

VivaGel[®] showed near complete antiviral protection against Zika virus in laboratory studies at concentrations significantly below that used in the Dual Protect[™] VivaGel[®] condom



Australian Olympic team will be given double-strength condoms to take to Rio due to Zika virus fears

Bacterial Vaginosis and VivaGel[®] BV: Two product opportunities


Bacterial Vaginosis (BV):

- Most common vaginal infection worldwide
- ~29% women infected in US; up to 51% in some groups
- Recurrent BV an issue in 50-60% of BV sufferers
- Current therapies have low cure rates and nasty side effects
- No approved products for Recurrent BV (R-BV)

Large market opportunity for both prevention of R-BV and BV Symptomatic Relief



Trial Participants




VivaGel[®] BV: Product Proposition

- a <u>non-antibiotic therapy</u>
- management of BV symptoms and prevention of R-BV
- a selective antimicrobial effect for pathogens that cause BV
- a local effect and is not systemically
 absorbed
- bio- adhesive properties



VivaGel® BV: Two attractive commercial opportunities






Partner engagement underway for both opportunities

VivaGel[®] BV Treatment & Symptomatic Relief of BV

- VivaGel[®] BV gains EU approval for the treatment and rapid relief of BV
- Allows for marketing in 28 EU countries & EFTA countries (population >260m women)
- EU approval will be used as the basis for obtaining marketing approvals for VivaGel[®] BV in other countries
- Discussions regarding marketing rights for VivaGel[®] BV underway with a number of potential commercial partners
- Current global market for the management of BV is estimated to be ~US\$750 million annually



VivaGel[®] BV is a unique topical vaginal gel. Its proprietary active is not absorbed and acts locally to suppress the pathogens that cause BV and the associated signs and symptoms.




starpharma

"It was like gone almost overnight"

- "I would definitely use it again."
- "The next day I noticed a huge difference."
- "I will use it indefinitely…"

VivaGel® BV Trial Participants



- Licence signed with Aspen for ANZ for Symptomatic Relief product
- Commercial discussions for multiple other territories underway
- 2016 launch planned for Symptomatic Relief

starpharma

Agrochemicals

Starpharma's Priostar[®] Agrochemical Programs



Partnered Priostar® Programs

- Adama have licensed SPL's Priostar[®] for novel and improved 2,4-D products for the US market
- Multiple new agreements have been signed or extended with major agrochemical companies for the European, Asian and North American markets
- Collaboration with major Japanese agrochemical company;



- Multiple potential opportunities for revenue streams
- Estimated value of partners share of market for actives under development: >US\$5B

Internal Priostar[®] Programs

• Regulatory compliant field trials of Priostar[®] enhanced versions of several major herbicide and fungicide formulations completed showing a number of commercially compelling benefits

Glyphosate	(\$4-5B)	Improve efficacy				
Glyphosinate NI	H ₄ (\$400m)	Improve Efficacy				
Metolachlor	(\$605m)	Improve efficacy				
Deltamethrin	(\$340m)	Improve efficacy/ low solvent				
Propiconazole	(\$350m)	Improve efficacy / Loading				
Imidacloprid	(>\$1B)	Improve efficacy / Loading				

Priostar[®] benefits for innovative crop protection formulations

Better in the can:

- Solubility enhancement
- Increased loading
- Formulation stability
- Reduction/removal of solvents – "greener" formulations

Better in the field:

- Increased efficacy
- Modification of soil penetration
- Protection of Actives



Adama Licenses Priostar[®] for novel 2,4-D products



- Adama have licensed SPL's Priostar[®] for novel, improved 2,4-D products for the US market
- Priostar[®] enhanced product expected to provide better flexibility, weed control and improved safety
- SPL to receive royalties; Adama to fund development and registration
- 2,4-D is the second largest herbicide globally with sales of US\$680m

ADAMA

"The innovative nature and superior performance of the Priostar[®] formulations fit well with our strategy to deliver simple and efficient solutions to farmers to help them grow."

> Sami Shabtai, Head of Innovative Development at Adama

Adama is one of the world's leading crop protection companies with annual sales of US\$3.2b and one of the most comprehensive portfolios of differentiated products sold in more than 120 countries. Adama is privately held by ChemChina and Koor Industries.

Expected News Flow



VivaGel[®] Portfolio:

- Further regulatory approvals for VivaGel[®] BV for Treatment & Symptomatic Relief
- Further licenses for VivaGel[®] BV product marketing (multiple territories)
- Launch VivaGel[®] BV for Treatment & Symptomatic Relief
- Progress and completion of VivaGel[®] BV Phase 3 BV Prevention of Recurrence trials
- Further approvals/geographic roll-out of the VivaGel[®] condom and commercial developments post Zika activity

DEP™ Drug Delivery:

- Completion of DEP[™] docetaxel Phase 1 clinical trial and commencement of Phase 2
- AZ and other Partnered program announcements (further compounds advanced) and new DEP[™] deals
- Advance additional DEP[™] candidates through preclinical and into clinic

Priostar® Dendrimers in Agrochemicals:

- Progress with Adama 2,4-D licence
- Further Priostar[®] licences with partners and regional expansion of existing deals
- Advance internal Priostar[®] candidates eg. glyphosate (Roundup[®]) ; regulatory-compliant field trials and re-registration activities to support commercialisation

For Further Information

Dr Jackie Fairley, CEO +61 3 8532 2704 <u>Investor.relations@starpharma.com</u> Twitter: @Starpharma_ASX





